Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 10, Issue 10, Pages 1615-1629Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560902980202
Keywords
antiretroviral therapy; atazanavir; darunavir; drug resistance; HIV; protease inhibitors; tipranavir
Categories
Ask authors/readers for more resources
Background: HIV protease inhibitors (Pis) are potent antiretroviral drugs that represent a pivotal component of highly active antiretroviral therapy (HAART). Pis have evolved over the years to gain in potency, convenience, tolerability and genetic barrier to resistance. Objective: Updated summary of evidence-based information about the efficacy and safety of Pis on initial, simplification and rescue interventions in HIV patients. Methods: Review of available data reported in peer-reviewed journals, medical conferences and treatment guidelines. Results: Due to their characteristics, Pis are, and will remain, a cornerstone component in most lines of antiretroviral therapy. The antiviral activity, tolerability and convenience of Pis have improved significantly in recent years. Differences between compounds within this class may favour their use in specific situations, such as the friendly metabolic profile of atazanavir in patients with cardiovascular disease or the high genetic barrier of darunavir or tipranavir in heavily pretreated individuals with HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available